OncoMatch/Clinical Trials/NCT07143812
A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma
Is NCT07143812 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies MSC11FCD for glioblastoma (gbm).
Treatment: MSC11FCD — This is a phase I clinical trial evaluating the safety, tolerability, and maximum tolerated dose of MSC11FCD, an investigational allogeneic bone marrow-derived mesenchymal stem cell therapy expressing a suicide gene, in patients with newly diagnosed glioblastoma. The investigational product is administered intratumorally following surgical resection. This study aims to explore whether MSC11FCD can provide a targeted, localized treatment option during the postsurgical period, potentially addressing residual tumor cells and reducing early recurrence.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: standard therapy for glioblastoma
after receiving standard therapy for glioblastoma
Cannot have received: immunotherapy
Patients who have not received any other types of immunotherapy
Cannot have received: Gliadel wafer (Gliadel wafer)
Patients who received Gliadel wafer implantation during surgery
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify